Why the study?
What are the pharmacokinetic properties of disopyramide in patients recovering from myocardial infarction?
What are the pharmacokinetic properties of disopyramide in patients recovering from myocardial infarction?
In patients recovering from MI with normal renal function, a standard loading dose of 2 mg/kg of disopyramide followed by maintenance dosing 3-4 times daily is appropriate due to reduced volume of distribution and clearance.
Answers are grounded in this paper and cite their sources.
May guide disopyramide dosing post-MI; leaves open prospective validation before practice change.
1 Previous pharmacokinetics studies of disopyramide in patients with ischaemic heart disease include unexplained reports of poor bioavailability and extremely long elimination half-lives which undermine accepted dosage recommendations. 2 Disopyramide pharmacokinetics were investigated after intravenous and oral administration to nine such patients. 3 Mean elimination half-life (6.82 h) and bioavailability (79.8%) were consistent with findings from a previous study in young healthy volunteers. 4 Volume of distribution was reduced by 25%: the mean +/- s.d. value was 0.61 +/- 0.17 l/kg. Total body clearance was significantly reduced: the mean +/- s.d. value was 1.02 +/- 0.16 ml min-1 kg-1. 5 These figures indicate that, in this patient group, if renal function is not significantly impaired, a standard loading dose of 2 mg/kg should be followed by the appropriate maintenance dose administered three or four times daily.
No takes yet. Share an insight, caveat, or question.
Bryson et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: